TeslaDuo Technologies

📣 #tesladuo is undergoing a significant transformation as we shift our entire business model to focus on a Decentralized Autonomous Organization dedicated to #researchanddevelopment in various areas. TeslaDuo Research, the newly rebranded #LLC DAO, will be using the existing $OVS native token as it strongly aligns with the goals, values, and objectives of OmniversalisDAO for more synergies & connection with the broader ecosystem. 🔬 Our primary areas of focus remain #ai & #ml , (AI) #smartcontracts, 3rd generation #Blockchain, #lifesciences, and #healthcare, encompassing #drugdiscovery, #drugdevelopment , #genetherapy, #precisionmedicine, #femtech, #aging, and more. 🚀 As we embrace this new direction, we are excited to embark on a journey that combines scientific creativity, technological ingenuity, and a passion for lifesciences, & healthcare. We take pride in being the funders, co-founders & co-owners of our LLC DAOs, assuming full responsibility for their long-term success by providing comprehensive resources within our ecosystem. With this new approach, we aim to revolutionize industries, challenge the status quo, and make a meaningful impact on society. By leveraging the power of the #dao model, we will collaborate with #experts, #researchers, and visionaries to shape a future driven by innovation and social progress. We are thrilled about this exciting chapter and the opportunities it presents. As we embark on this transformative journey, we invite like-minded individuals & organizations to join us in our pursuit of technological breakthroughs & societal advancement. Join our common #discordserver with our outer DAO, OmniversalisDAO, today & seize the opportunities that lie ahead! 💪🌟 👉 https://lnkd.in/eV5z3DeY Thank you for your continued support & enthusiasm. We look forward to sharing updates & collaborating with you as we venture into this new era of innovation. Tyler I. Sainkoudje Marie N. Mendez-Sainkoudje Caroline Rodriguez Samuel Craft Raphael Wenninger OmniversalisDAO Matrixed Health Group Omniversalis Impact Fund TheraVac Biotech Trade Pharma Network (TPN) BayesLearn Systems Sirrena #research #randd #innovation #daos #daoforcreators #web3governance #gouvernance #ovstoken #ovs

🚀 Advancing MPOX Clade 1B Research: A Novel Immunogenic Target Identified In our latest in silico study, we have uncovered a promising immunogenic region within one of the critical proteins of #MPOX, specifically targeting #Clade1b. This breakthrough holds potential for developing next-generation #vaccines, immunotherapies, and antiviral strategies against this challenging viral strain. 🌟 Why It Matters 👉 Clade 1B Specificity: Our findings are tailored to tackle the unique characteristics of MPOX Clade 1B, addressing an urgent need in virology and infectious disease research. 👉 Actionable Insights: The identified immunogenic region offers a direct pathway for therapeutic innovation. 🧬 What’s Next? Request our study to explore the full potential of these findings. Let’s collaborate to validate and translate this discovery into real-world applications. 📢 Opportunities Licensing options & collaborative projects are available for organizations ready to advance this research. Partial IP rights may be granted to partners interested in scaling the development of these groundbreaking strategies. 💡 Join Us Be part of this transformative effort to outpace MPOX with cutting-edge science. Contact us to request the study and discuss next steps. Together, let’s lead the way in infectious disease innovation. Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger Omniversalis Impact Fund BayesLearn Systems SirrenaAI TradePharma Network TradePharmaDAO OmniversalisDAO #Innovation #RnD #Biotech #LifeScience #TheraVacBiotech #InSilico #AIinHealthcare #GlobalHealth #VaccineDevelopment #PeptideVaccine #Vaccine #PrecisionMedicine #Immunotherapy

🚀🌟 Revolutionizing Cancer Therapy with AI 🌟🚀 We’re thrilled to share a major milestone in the fight against cancer: the development of TheraVac-AC-2, a novel peptide vaccine targeting the KRAS G12D mutation, a key driver in aggressive cancers like pancreatic & colorectal cancer. 🎯 Leveraging AI-driven peptide engineering and cutting-edge in silico validation (65% success in docking simulations! 💻🔬), TheraVac-AC-2 is now positioned as a promising candidate for preclinical studies. This achievement reflects the power of human-AI collaboration to accelerate breakthrough therapies in oncology. 🔑 Key Highlights: ✅ AI-guided identification of the optimal peptide inhibitor. ✅ Structural validation using AlphaFold and docking simulations with SwissDock, showcasing strong binding affinity. ✅ A reproducible, open pathway for researchers to test TheraVac-AC-2 in wet-lab settings. At #TheraVacBiotech, we believe in the power of innovation & collaboration to drive meaningful progress in cancer treatment. Stay tuned as we continue to push boundaries in precision medicine! 💬 What’s next? We’re exploring partnerships with #biotech and #lifesciences leaders to bring this groundbreaking therapy closer to reality. Let’s connect if you’re passionate about advancing oncology & life sciences! Dr. Isaad Sainkoudje Sirrena Caelis Marie N. Mendez-Sainkoudje Caroline Rodriguez Samuel Craft Raphael Wenninger TradePharma Network TradePharmaDAO Omniversalis Impact Fund BayesLearn Systems SirrenaAI OmniversalisDAO #Innovation #Oncology #AIinScience #AIinHealthcare #KRASG12D #PeptideVaccine #RnD #Biotech #InSilico #NeoAntigens #PeptideVaccine #PrecisionMedicine #DeSci

🚀 The Future of Movement is Here! We’re excited to unveil our latest video for OmniTwin, where innovation meets freedom. 🌟 Whether you’re an explorer, creator, or visionary, OmiTwin is designed to empower your journey, adapt to your world, and elevate how you move. 🌍✨ 🎥 Watch the video & experience the transformation. It’s time to redefine what’s possible and take control of every path ahead. Your potential. Your journey. Your OmiTwin. Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger SirrenaAI OmniversalisDAO Omniversalis Impact Fund #EmpoweredMotion #OmiTwinExperience #InnovationUnleashed #FutureOfMovement #ElevateYourJourney #SmartTech #Sustainability #FreedomToMove #TechForTomorrow #MVP #OmiTwin

This development serves as a sobering reminder of the global threat posed by emerging infectious diseases like #MPOX. At TheraVac Biotech, we’re fully aware of the situation and working tirelessly to address it. 🚨 One #MPOX vaccine in our pipeline is TheraVac-MPOX-1: a novel biologic targeting two of the most promising genes/proteins among the six involved in MPOX pathogenesis, including #Clade1b. These proteins are critical to the virus's ability to infect host cells, expand its host range, and evade the immune system—making them prime candidates for therapeutic interventions. 🧬💉 As we advance this and other cutting-edge research projects, we remain committed to accelerating innovative solutions to combat global health threats. Together, we can build a more resilient future. 🌍🔬 Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger Omniversalis Impact Fund BayesLearn Systems SirrenaAI OmniversalisDAO #Innovation #RnD #Biotech #LifeScience #TheraVacBiotech #InSilico #AIinHealthcare #GlobalHealth #VaccineDevelopment #PeptideVaccine #Vaccine #PrecisionMedicine #Immunotherapy

Welcome to OmniTwin’s LinkedIn! We're here to transform industries through digital twins, advanced AI, and cutting-edge simulations. Let’s shape the future together—one twin at a time! 🌍✨ Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger TheraVac Biotech TeslaDuo Research SirrenaAI TradePharma Network TradePharmaDAO Omniversalis Impact Fund #AI #Decentralization #DigitalIdentity #DigitalTwins #CredentialingProcess #TechInnovation #Collaboration #Blockchain #Web3 #OmniTwin #OmniComm

🚀 In Progress: NeoVax Development for High-Impact Cancer Neoantigens 🚀 We're excited to share updates on the ongoing progress with #NeoVax, where we are harnessing top #neoantigen targets in our mission to advance personalized cancer immunotherapy. Below are the neoantigens currently being evaluated for their roles in driving aggressive cancers, with targeted mutation fragments, #HLA #binding data, and associated #cancer types: 1. KRAS (G12V)   - Associated Cancers: Pancreatic, colorectal, non-small cell lung cancer (NSCLC)   - HLA Type: HLA-A*11:01   - Binding Score: 35 nM (Strong Binding) 2. EGFR (L858R)   - Associated Cancers: NSCLC, glioblastoma   - HLA Type: HLA-A*02:01   - Binding Score: 80 nM (Intermediate Binding) 3. BRAF (V600E)   - Associated Cancers: Melanoma, colorectal, thyroid, NSCLC   - HLA Type: HLA-A*11:01   - Binding Score: 15 nM (Strong Binding) 4. HER2 (ERBB2)   - Associated Cancers: Breast, gastric, esophageal cancers   - HLA Type: HLA-A*02:01   - Binding Score: 120 nM (Intermediate Binding) 5. NY-ESO-1   - Associated Cancers: Melanoma, ovarian, lung, synovial sarcoma   - HLA Type: HLA-A*02:01   - Binding Score: 20 nM (Strong Binding) 6. MAGE-A3   - Associated Cancers: Melanoma, head and neck, bladder, lung cancers   - HLA Type: HLA-A*02:01   - Binding Score: 45 nM (Strong Binding) 7. WT1 (Wilms Tumor 1)   - Associated Cancers: Leukemia, ovarian, lung cancers   - HLA Type: HLA-A*02:01   - Binding Score: 30 nM (Strong Binding) 8. GPC3 (Glypican-3)   - Associated Cancers: Hepatocellular carcinoma (HCC), melanoma   - HLA Type: HLA-A*24:02   - Binding Score: 70 nM (Intermediate Binding) Each of these neoantigens shows potential for strong to intermediate binding with key HLA types, enhancing their immunogenicity and paving the way for highly personalized cancer treatments. #NeoVax is dedicated to refining these targets to bring transformative therapies to patients worldwide. Stay tuned as we move forward with innovative partnerships & groundbreaking results! Learn more and join us in shaping the future of precision oncology!🧬💡 Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger TradePharma Network TradePharmaDAO Omniversalis Impact Fund BayesLearn Systems SirrenaAI OmniversalisDAO #Innovation #RnD #Biotech #TheraVacBiotech #InSilico #AIinHealthcare #NeoAntigens #PeptideVaccine #PrecisionMedicine

🌍 Exploring UBI & Cryptocurrency: A New Era for Economic & Healthcare Inclusion Universal Basic Income (#UBI) has long been discussed as a way to address income inequality and provide basic financial security for all. With the rise of cryptocurrency, digital assets are now seen as a natural & scalable medium for UBI distribution—thanks to their accessibility, transparency, and global reach. 💡 Comparative Overview of UBI-Driven Cryptocurrencies In our recent analysis, we compared #Worldcoin, #Dogecoin, and #HOPE in the UBI space: - Worldcoin aims for UBI via biometric verification, ensuring unique distribution through advanced iris scanning. - Dogecoin leverages community strength and openness, though it doesn't pursue structured UBI. - $HOPE, however, takes a unique approach: it’s focused specifically on healthcare access through its Omniversalis Basic Income (#OBI) program, using #OmniTwin for privacy-centered ID verification & rewarding health-positive behaviours. 💜 The Unique Value of $HOPE $HOPE’s commitment to healthcare equity and data privacy sets it apart. By directly supporting underserved communities through a healthcare-focused UBI model, $HOPE ensures that its humanitarian mission aligns with impactful, real-world outcomes. 🚀 Future Implications As these UBI models evolve, they hold transformative potential for global economic inclusion and healthcare access, potentially reshaping how we address critical challenges worldwide. 🔗 To learn more about how $HOPE is pioneering a blend of economic and healthcare inclusion, stay tuned for our detailed article! Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Caroline Rodriguez Sirrena Caelis Samuel Craft Raphael Wenninger OmniversalisDAO Omniversalis Omniversalis Impact Fund TradePharma Network TradePharmaDAO SirrenaAI #DiplomaticHealthcare #DiplomacyForHealth #Blockchain #Innovation #BlockchainInnovation #HealthcareForAll #InclusionMatters #HumanitarianInnovation #HealthcareEquity #GlobalHealthcare #DAO #SmartContracts #CryptoForGood #HealthcareForAll #FutureOfFinance #MSi

🚀 Announcing NeoVax®: Pioneering Personalized Cancer Vaccines for the Future of Precision Medicine! 🚀 At #Genovate® Platform, we're thrilled to unveil #NeoVax®, a revolutionary module within TheraVac Biotech, focused on transforming cancer treatment through personalized neoantigen vaccines✨🌐 Why NeoVax®? NeoVax taps into the cutting-edge of immunotherapy by targeting unique mutations (neoantigens) in cancer cells, creating tailor-made vaccines designed to trigger a powerful immune response. Our precision-driven approach identifies, optimizes, and validates the most immunogenic fragments, offering new hope in the fight against aggressive cancers. How It Works NeoVax leverages AI-powered platforms for: 1- Neoantigen Identification & Selection - Harnessing Genovate’s data resources to pinpoint high-potential neoantigen targets. 2- Peptide Synthesis & Optimization - Utilizing molecular docking, MD simulations, and ADMET profiling to refine peptide designs. 3- Vaccine Formulation & Validation - Formulating vaccines through in silico and preclinical trials, moving towards clinical and regulatory milestones with high success projections. Seamless Collaboration & Compliance Integrated with the Genovate ecosystem, NeoVax bridges R&D with regulatory workflows through decentralized, transparent digital twins, ensuring compliance, data integrity, and accelerated approval processes. The Future of Cancer Treatment is Here NeoVax embodies a vision where precision medicine is accessible, tailored, and impactful for every patient. Together with our partners and the wider community, we’re bringing personalized cancer vaccines from concept to clinic. Stay tuned as we move forward with clinical trials, innovative partnerships, and groundbreaking results! Learn more and join us in shaping the future of precision oncology!🧬💡 Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger TradePharma Network TradePharmaDAO Omniversalis Impact Fund BayesLearn Systems SirrenaAI OmniversalisDAO #Innovation #RnD #Biotech #TheraVacBiotech #InSilico #AIinHealthcare #RegulatoryCompliance #Biologics #NeoAntigens #PreclinicalTrials #ClinicalTrials #PrecisionMedicine #OmniComm #OmniTwin

🚨🔬 TheraVac Innovations: Breaking News on Pipeline Developments Fueled by powerful datasets and backed by a dedicated GPU-based system with 128+ GB of RAM, over 5 KWatts of computing power, and just a few iterations away, we’ve made groundbreaking strides in developing our latest peptide therapy, reaching an impressive 65% success rate in #insilico tests targeting #aging & #neurodegenerative pathways—our best 'in silico' performance to date! 🚀 As an emerging biopharmaceutical startup specializing in #RNA, #DNA, and #peptideengineering technologies, we are thrilled to announce the advancement of our innovative TheraVac-AC-2 Peptide Vaccine into #preclinical studies. This achievement underscores the collaborative efforts of TheraVac Biotech and its partners to develop pioneering therapies addressing critical unmet needs in #oncology. About TheraVac-AC-2: TheraVac-AC-2 is a #novel #peptide therapy designed to selectively target cancer cells expressing the KRAS G12D mutation, which drives aggressive diseases like #pancreaticcancer and #colorectalcancer. By stimulating immune recognition of KRAS G12D-mutant cells, TheraVac-AC-2 aims to disrupt cancer progression and offer a new therapeutic avenue for patients with limited treatment options. With rigorous in silico validation, this promising candidate is now ready for synthesis and in vivo preclinical testing. Transition to Preclinical Studies: Following an extensive design and computational validation phase, TheraVac-AC-2 now progresses into in vivo preclinical studies. These studies will critically evaluate the vaccine’s safety, efficacy, and immune activation potential, setting the stage for a targeted immunotherapy that brings hope to KRAS-driven cancer treatment. Exploring Collaborations: As we advance TheraVac-AC-2, TheraVac Biotech is actively seeking partnerships with #lifesciences sponsors to support development and expand the therapeutic reach of this novel cancer vaccine. Collaborations with new partners are vital to accelerating TheraVac-AC-2’s journey to market, where it holds potential to transform oncology care. Looking Ahead: TheraVac remains committed to driving scientific innovation and establishing groundbreaking cancer therapies through rigorous evaluation & collaboration with leading partners in the #tech & life sciences fields. We look forward to updating our community as TheraVac-AC-2 progresses toward clinical trials, bringing fresh hope to patients with challenging cancers like those driven by KRAS G12D. Dr. Isaad Sainkoudje Marie N. Mendez-Sainkoudje Sirrena Caelis Caroline Rodriguez Samuel Craft Raphael Wenninger TeslaDuo Research TradePharma Network TradePharmaDAO OmniversalisDAO SirrenaAI BayesLearn Systems #Biotech #Innovation #DrugDiscovery #KRAS #G12D #AI #Sirrena #BayesLearnSystem #PeptideEngineering #PeptideVaccine #PrecisionMedicine #IPprotection #NFT #Discoveria #TokenZu #Genovate #TheraVac